WO2009021750A3 - Benzoxazole, benzimidazole and benzothiazole derivatives and their use in the treatment of duchenne muscular dytrophy - Google Patents

Benzoxazole, benzimidazole and benzothiazole derivatives and their use in the treatment of duchenne muscular dytrophy Download PDF

Info

Publication number
WO2009021750A3
WO2009021750A3 PCT/EP2008/006720 EP2008006720W WO2009021750A3 WO 2009021750 A3 WO2009021750 A3 WO 2009021750A3 EP 2008006720 W EP2008006720 W EP 2008006720W WO 2009021750 A3 WO2009021750 A3 WO 2009021750A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
dytrophy
benzoxazole
benzimidazole
duchenne muscular
Prior art date
Application number
PCT/EP2008/006720
Other languages
French (fr)
Other versions
WO2009021750A2 (en
Inventor
Graham Michael Wynne
Olivier De Moor
Cristina Lecci
Renate Van Well
Peter David Johnson
Richard Storer
Severine Poignant
Stephen Paul Wren
Original Assignee
Biomarin Iga Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Iga Limited filed Critical Biomarin Iga Limited
Priority to CN2008800160060A priority Critical patent/CN102036972A/en
Priority to CA002685605A priority patent/CA2685605A1/en
Priority to AU2008286326A priority patent/AU2008286326A1/en
Priority to JP2010520500A priority patent/JP2010535831A/en
Priority to MX2009012203A priority patent/MX2009012203A/en
Publication of WO2009021750A2 publication Critical patent/WO2009021750A2/en
Publication of WO2009021750A3 publication Critical patent/WO2009021750A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C07F9/65324—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

There are disclosed compounds of Formula (1). Pharmaceutical compositions containing the compounds are also provided. Methods of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy and cachexia using the compounds and compositions are also provided.
PCT/EP2008/006720 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy WO2009021750A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2008800160060A CN102036972A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
CA002685605A CA2685605A1 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy
AU2008286326A AU2008286326A1 (en) 2007-08-15 2008-08-14 Treatment of Duchenne muscular dystrophy
JP2010520500A JP2010535831A (en) 2007-08-15 2008-08-14 Treatment of Duchenne muscular dystrophy
MX2009012203A MX2009012203A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0715939.5A GB0715939D0 (en) 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy
GB0715939.5 2007-08-15

Publications (2)

Publication Number Publication Date
WO2009021750A2 WO2009021750A2 (en) 2009-02-19
WO2009021750A3 true WO2009021750A3 (en) 2014-02-20

Family

ID=38566449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/006720 WO2009021750A2 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy

Country Status (8)

Country Link
JP (1) JP2010535831A (en)
CN (1) CN102036972A (en)
AU (1) AU2008286326A1 (en)
CA (1) CA2685605A1 (en)
GB (1) GB0715939D0 (en)
MX (1) MX2009012203A (en)
TW (1) TW200914430A (en)
WO (1) WO2009021750A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905667D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2818903C (en) * 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
US9246108B2 (en) * 2012-12-28 2016-01-26 Dow Global Technologies Llc Quinoline-benzoxazole derived compounds for electronic films and devices
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
BR112018070076A2 (en) * 2016-03-30 2019-05-21 Summit (Oxford) Limited composition for the treatment of duchenne muscular dystrophy
CN113264894A (en) * 2021-05-24 2021-08-17 陕西维世诺新材料有限公司 Benzoxazole derivative and preparation method thereof
WO2023175010A1 (en) 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Use of bazedoxifene for increasing muscle survival

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058896A1 (en) * 2000-02-11 2001-08-16 Darwin Discovery Limited Benzoxazole derivatives as tnf and pde iv inhibitors
US6372736B1 (en) * 1998-07-21 2002-04-16 Pfizer Inc Heterocyclic compounds as inhibitors of rotamase enzymes
US20030171412A1 (en) * 2001-12-13 2003-09-11 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
WO2004041277A1 (en) * 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1454627A1 (en) * 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
EP1460067A1 (en) * 2001-11-26 2004-09-22 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
EP1547996A1 (en) * 2002-08-30 2005-06-29 BF Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
WO2007091106A2 (en) * 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372736B1 (en) * 1998-07-21 2002-04-16 Pfizer Inc Heterocyclic compounds as inhibitors of rotamase enzymes
WO2001058896A1 (en) * 2000-02-11 2001-08-16 Darwin Discovery Limited Benzoxazole derivatives as tnf and pde iv inhibitors
EP1460067A1 (en) * 2001-11-26 2004-09-22 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
US20030171412A1 (en) * 2001-12-13 2003-09-11 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
EP1547996A1 (en) * 2002-08-30 2005-06-29 BF Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
WO2004041277A1 (en) * 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1454627A1 (en) * 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
WO2007091106A2 (en) * 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
CA2685605A1 (en) 2009-02-19
JP2010535831A (en) 2010-11-25
CN102036972A (en) 2011-04-27
GB0715939D0 (en) 2007-09-26
TW200914430A (en) 2009-04-01
AU2008286326A1 (en) 2009-02-19
WO2009021750A2 (en) 2009-02-19
MX2009012203A (en) 2009-12-18

Similar Documents

Publication Publication Date Title
WO2009021750A3 (en) Benzoxazole, benzimidazole and benzothiazole derivatives and their use in the treatment of duchenne muscular dytrophy
MX2009012558A (en) Drug combinations for the treatment of duchenne muscular dystrophy.
WO2009019505A3 (en) Drug combinations for the treatment of duchenne muscular dystrophy
WO2008101682A3 (en) Iminipyridine derivatives and their uses as microbiocides
MX2010003156A (en) Tetrazole-substituted aryl amide derivatives and uses thereof.
MX2010009163A (en) Heterocyclic urea derivatives and methods of use thereof-211.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
EP3091019A3 (en) Purine derivatives useful as hsp90 inhibitors
WO2009121623A3 (en) Compounds for treating muscular dystrophy
IL204437A (en) Cyclopropyl aryl amide derivatives and uses thereof
MX2010003868A (en) Chiral cis-imidazolines.
WO2010003475A3 (en) Novel pyrrolidone derivatives for use as metap-2 inhibitors
WO2010020432A3 (en) Compounds for treatment of duchenne muscular dystrophy
WO2010004197A3 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
MX2010009022A (en) 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use.
WO2009046842A3 (en) Thiazol derivatives for treating cancer
NO20084853L (en) Compounds that are agonists of muscarinic receptors and which may be effective in the treatment of pain, Alzheimer's disease and / or schizophrenia
MX2010008921A (en) Oxazolidinone derivatives.
MX2010005824A (en) Aminothiazole derivatives.
WO2008006795A3 (en) Indole compounds
WO2008147557A3 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
UA95715C2 (en) Phosphadiazine derivatives, pharmaceutical composition and use thereof
EP2401263A4 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2010067078A8 (en) 3,6-disubstituted xanthylium salts
MX2009013501A (en) Piperidine compounds and uses thereof.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880016006.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2685605

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010520500

Country of ref document: JP

Ref document number: 6655/CHENP/2009

Country of ref document: IN

Ref document number: MX/A/2009/012203

Country of ref document: MX

Ref document number: 2008785567

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008286326

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008286326

Country of ref document: AU

Date of ref document: 20080814

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08785567

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08785567

Country of ref document: EP

Kind code of ref document: A2

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0811138

Country of ref document: BR